Compare ZURA & TLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZURA | TLS |
|---|---|---|
| Founded | 2022 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.4M | 358.0M |
| IPO Year | 2021 | 2020 |
| Metric | ZURA | TLS |
|---|---|---|
| Price | $4.14 | $4.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $18.00 | $6.33 |
| AVG Volume (30 Days) | ★ 1.5M | 621.2K |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.51 |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $164,805,000.00 |
| Revenue This Year | N/A | $16.14 |
| Revenue Next Year | N/A | $0.26 |
| P/E Ratio | ★ N/A | $135.67 |
| Revenue Growth | N/A | ★ 52.21 |
| 52 Week Low | $3.15 | $3.79 |
| 52 Week High | $7.25 | $8.36 |
| Indicator | ZURA | TLS |
|---|---|---|
| Relative Strength Index (RSI) | 32.37 | 46.50 |
| Support Level | $3.90 | $4.07 |
| Resistance Level | $5.87 | $4.68 |
| Average True Range (ATR) | 0.29 | 0.14 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 18.75 | 57.65 |
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
Telos Corp offers technology solutions and services that empower and protect the world's security-conscious organizations. The company delivers efficient, adaptable, and secure solutions that protect people, organizations, and information across government and industry. The company conducts its business through two reportable and operating segments: Security Solutions and Secure Networks. The Security Solutions segment is focused on cybersecurity, cloud, and identity solutions, and secure messaging through Xacta, Telos AMHS, and Telos ID offerings. The Secure Networks segment provides secure networking architectures and solutions to customers through secure mobility solutions, network management, and defense services. The majority of revenue is from Secure Networks.